<unk> s are used primarily for the treatment of diabetes mellitus type 2.<unk> s are ineffective where there is absolute deficiency of insulin production<unk> ch as in type 1 diabetes or post-pancreatectomy.<unk> s can be used to treat some types of neonatal diabetes. While historically, people with hyperglycemia and low blood insulin levels were diagnosed with type 1 diabetes by default, it has been found that patients who receive this diagnosis before 6 months of age are often, in fact, candidates for receiving<unk> s rather than insulin throughout life. A 2011 Cochrane systematic review evaluated the effects on treatment of Latent Autoimmune Diabetes in Adults (LADA) and found that<unk> s did improve metabolic control of glucose at 3 and 12 months, even worsening HbA1c levels in some cases, when compared to insulin. The same review did not find improvement of fasting C-peptide following treatment with<unk> . Still, it is important to highlight that the studies available to be included in this review presented considerable flaws in quality and design. While prior<unk> s were associated with worse outcomes, newer agents do not appear to increase the risk of death, heart attacks, or strokes.
Sulfonylurea
Aminosalicylate
Omega-3 carboxylic acids
Anthopleurin
Niclosamide
Allopurinol
Bisphosphonate
Retinoid